Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-02-21

Clinical Trial Update: PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

Phase 3 PHIRST-1 trial evaluating tadalafil for pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TADALAFIL (TADALAFIL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED